Form 4: Adial Pharmaceuticals CFO Vinay Shah Acquires 40,000 Stock Options

Adial Pharmaceuticals' Chief Financial Officer, Vinay Shah, was granted 40,000 stock options on November 16, 2024.

Summary

• Vinay Shah, the Chief Financial Officer of Adial Pharmaceuticals, acquired 40,000 stock options on November 16, 2024.
• The options have an exercise price of $1.06 per share.
• The options vest pro rata on a monthly basis over 36 months.
• The options expire on November 15, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There is no indication of any negative or unusual activity.

Positives

• The granting of stock options to the CFO aligns his interests with the company's long-term performance.
• The vesting schedule encourages the CFO's continued service and contribution to the company over the next three years.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of 36 months is typical for such grants, encouraging long-term commitment from the executive.
• The exercise price of $1.06 is specific to Adial Pharmaceuticals and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the company performs well and the options become valuable.
• The grant incentivizes the CFO to work towards the company's success, which benefits all stakeholders.

Key Dates

Keywords

stock options, insider trading, executive compensation, Adial Pharmaceuticals, Vinay Shah, ADIL